Loading...
•
Mar 31, 2025
Corcept Therapeutics Q1 2025 Earnings Report
Corcept Therapeutics announced first quarter financial results and provided a corporate update
Key Takeaways
Corcept Therapeutics reported revenue of $157.2 million for the first quarter of 2025, an increase from $146.8 million in the same period last year. Despite a decrease in net income and diluted EPS compared to the prior year, the company reiterated its full-year 2025 revenue guidance of $900 - $950 million.
First quarter 2025 revenue was $157.2 million, up from $146.8 million in Q1 2024.
Net income for Q1 2025 was $20.5 million, down from $27.8 million in Q1 2024.
Diluted EPS was $0.17 in Q1 2025, compared to $0.25 in Q1 2024.
Cash and investments totaled $570.8 million as of March 31, 2025.
Revenue by Segment
Forward Guidance
Corcept Therapeutics reiterated its full-year 2025 revenue guidance and provided updates on its clinical development programs.
Positive Outlook
- Reiterated 2025 revenue guidance of $900 – $950 million.
- NDA for relacorilant in hypercortisolism progressing towards approval by year-end 2025.
- NDA submission expected next quarter for relacorilant in platinum-resistant ovarian cancer.
- ROSELLA trial met primary endpoint of improved progression-free survival in platinum-resistant ovarian cancer.
- Promising early results from the CATALYST study on the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes.
Challenges Ahead
- Q1 2025 financial results negatively affected by specialty pharmacy vendor's inability to fulfill demand.
- DAZALS study did not meet the primary endpoint of improvement in ALSFRS-R in patients with ALS.
- Net income and diluted EPS decreased compared to the first quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...